Drug Sales Trends for ANDROGEL

Payment Methods and Pharmacy Types for ANDROGEL (2012)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
MAIL-ORDER	$257,635,758
INSIDE ANOTHER STORE	$228,836,976

Units Sold by Pharmacy Type

Pharmacy Type	Units
MAIL-ORDER	456,463
INSIDE ANOTHER STORE	648,064

Revenues by Payment Method

Payment Method	Revenues
MEDICARE	$397,022,921
PRIVATE INSURANCE	$443,505,717

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for ANDROGEL

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
ANDROGEL			2022
ANDROGEL			2021
ANDROGEL			2020
ANDROGEL			2019
ANDROGEL			2018
ANDROGEL			2017
ANDROGEL			2016

Market analysis and sales projections for ANDROGEL

Last updated: February 13, 2026

Overview

ANDROGEL is a topical androgen replacement therapy (TRT) for men diagnosed with hypogonadism. The product contains testosterone gel (1%) and is marketed by AbbVie. The global androgen replacement market has exhibited consistent growth driven by aging populations, increasing awareness of hypogonadism, and expanding treatment options.

Market Size and Segments

• Global Testosterone Replacement Therapy (TRT) Market:

  • Valued at approximately $2.3 billion in 2022.
  • CAGR projected at 8.2% from 2023 to 2028 (ResearchandMarkets).
  • North America accounts for 60% of sales, due to high awareness and treatment rates.
  • Europe represents around 20%, with the remainder split between Asia-Pacific and other regions.

• Market Segments:

  • Topical gels (including ANDROGEL): 55%
  • Injections: 25%
  • Patches and other formulations: 20%

Competitive Landscape

• Leading brands include ANDROGEL, Testim, Axiron, Depo-Testosterone, and Natesto.
• ANDROGEL holds approximately 25% of the topical segment, with sales growth outpacing some competitors due to brand recognition and ease of use.

Pricing and Reimbursement

• Average retail price for ANDROGEL is around $350 per month per patient (source: GoodRx).
• Insurance reimbursement varies, influencing patient access and adherence.
• Cost increases driven by high-dose formulations and new delivery systems.

Regulatory Status and Patent Landscape

• ANDROGEL received FDA approval in 2000.
• Patent filings for formulations extend until approximately 2030.
• Introduces potential for generic competition post-patent expiry, which could impact sales.

Sales Projections

• 2022 baseline: Approximate sales of $400 million globally, with US sales constituting 85% of total.
• Growth assumptions:
  • Continued increase in hypogonadism diagnoses (~3-4% annual growth in aging male populations).
  • Increasing awareness and treatment acceptance.
  • Price stability, though potential discounts and patent cliffs could moderate growth.
• Forecast (2023–2027):
  • CAGR of 5% to 7%, assuming steady market growth and retention of brand market share.
  • By 2027, global sales could reach approximately $600-$700 million.
  • US sales expected to grow at similar rates, potentially reaching $550 million, accounting for up to 78% of total global revenue.

Factors Affecting Growth

• Market penetration in emerging markets depends on regulatory approvals and infrastructure.
• Patient adherence influenced by ease of application and side effect profiles.
• Generic entry post-patent expiration may reduce prices and sales volumes.
• New formulations or combo therapies could capture additional market share.

Risks and Challenges

• Regulatory delays for new formulations.
• Safety concerns, such as cardiovascular risks associated with TRT, may impair market growth.
• Competitive innovations, such as nasal gels or longer-acting injections, could threaten market share.

Summary Table

Year	Global Sales (Millions USD)	US Market Share	CAGR (%)	Notes
2022	400	85%	—	Current baseline
2023	420–430	78–80%	5–6	Stabilizing growth with market maturation
2024	445–455	78–80%	4–5	Increased awareness, stable prices
2025	470–490	77–79%	4–6	Impact of new competitors or formulations
2026	510–530	76–78%	4–6	Patent expiration risks potentially materializing
2027	600–700	75–78%	5–7	Possible expansion into non-US markets

Key Takeaways

• ANDROGEL holds a significant share within the topical TRT market.
• Sales are expected to grow modestly in line with overall market expansion.
• Patent expiries and competition from generics could influence long-term revenues.
• Growth potential exists in emerging markets with regulatory clearance and infrastructure investment.
• Market risks include safety concerns and innovative therapy entrants.

FAQs

1. What drives demand for ANDROGEL?
   Aging male population, increased diagnosis of hypogonadism, and preference for topically administered testosterone.

2. How vulnerable is ANDROGEL to generic competition?
   Patent protections extend until roughly 2030, limiting immediate generic entry but leading to potential price reductions afterward.

3. What pricing strategies impact ANDROGEL’s sales?
   High retail pricing and variable insurance reimbursement influence patient access and adherence, affecting overall sales.

4. Are there emerging alternatives threatening ANDROGEL?
   Yes, longer-acting injectables, oral testosterone formulations, and nasal gels are potential competitors.

5. What regional factors influence sales projections?
   Regulatory approval, healthcare infrastructure, reimbursement policies, and market awareness shape regional sales growth.

Sources

[1] Research and Markets. "Global Testosterone Replacement Therapy Market Report," 2023.
[2] GoodRx Pricing Data, 2023.
[3] FDA Database, 2020-2023.
[4] EvaluatePharma, "Topical Testosterone Market Share," 2022.